of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such a filing.

Director — Michael Amoroso: Mr. Amoroso resigned from the Board of Directors for personal reasons.

Results of Operations and Financial Condition. On May 13, 2026, Abeona Therapeutics Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026. On the same date, the Company posted on its investor relations website, located at investors.abeonatherapeutics.com, a presentation that will be used by management during the Company’s earnings conference call (the “Earnings Presentation”). A copy of the press release and the Earnings Presentation…

Director (Class 1) and Chair of the Audit Committee — Keith A. Goldan: Mr. Goldan was appointed as a new director and chair of the Audit Committee.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in

Entry into a Material Definitive Agreement. On July 18, 2025, Abeona Therapeutics Inc., a Delaware corporation (the “ Company ”) and its subsidiaries MacroChem Corporation, a Delaware corporation, and Abeona Therapeutics LLC, an Ohio corporation, entered into an amendment (the “ Amendment ”) to the Loan and Security Agreement (the “Agreement”) and Supplement to the Agreement, both dated January 8, 2024 (collectively, the “ Loan Agreement ”), with Avenue Venture Opportunities Fund, L.P., a Del…

Completion of Acquisition or Disposition of Assets. On June 27, 2025, Abeona Therapeutics Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The Company was awarded the voucher on April 28, 2025, under a U.S. Food and Drug Administration (“FDA”) program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV upon approval o…

Results of Operations and Financial Condition. On July 2, 2025, the Company issued a press release in relation to the Asset Sale, in which the Company announced that as of June 30, 2025, including the net proceeds from the Asset Sale, the Company’s unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in this item, including Exhibi…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Entry into a Material Definitive Agreement On May 9, 2025, Abeona Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The Company was awarded the voucher by the U.S. Food and Drug Administration (“FDA”) on April 28, 2025, upon approval of the Company’s biologics license application for ZEVASKYN™ (prademagene zamikerace…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. On November 14, 2024, Abeona Therapeutics Inc. (the “Company”) issued a press release entitled “Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates” regarding its financial results for the quarter ended September 30, 2024. The full text of the press release is filed as. Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein. The information in

Director — Bernhardt G. Zeiher, MD, FCCP, FACP and Eric Crombez, MD: Dr. Zeiher and Dr. Crombez were appointed as independent directors of the Board.

Results of Operations and Financial Condition. On August 12, 2024, Abeona Therapeutics Inc. issued a press release entitled “Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission” regarding its financial results for the quarter ended June 30, 2024. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein. The information in

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Entry into a Material Definitive Agreement. On May 3, 2024, Abeona Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Underwriter”) relating to the issuance and sale of an aggregate of (a) 12,285,056 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 6,142,656 shares of the Company’s common stock (the “Pre-Funded Warrants”) in an underwritten offer…

Other Events. On May 2, 2024, the Company delivered written notice to the placement agent that it was suspending and terminating the prospectus supplement, dated June 7, 2023 (the “ATM Prospectus Supplement”), to the prospectus dated October 22, 2021, relating to up to $106,000,000 of the Company’s common shares that may be issued and sold pursuant to the Open Market Sale Agreement SM , dated as of August 17, 2018, as amended, by and between the Company and the placement agent (the “Sales Agr…

Results of Operations and Financial Condition. Abeona Therapeutics Inc. ( the “Company” ) expects to report that, as of March 31, 2024, the Company’s cash, cash equivalents, restricted cash and short-term investments were approximately $62.7 million. This financial information is preliminary and subject to change in connection with the completion of the Company’s financial statements for the quarter ended March 31, 2024. The Company’s independent registered public accounting firm has not audi…

The filing is about the approval of an equity incentive plan, not a management change.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Entry into a Material Definitive Agreement. Loan and Security Agreement On January 8, 2024 (the “ Closing Date ”), Abeona Therapeutics Inc., a Delaware corporation (“ Abeona ”) and its subsidiaries MacroChem Corporation, a Delaware corporation (“ MacroChem ”) and Abeona Therapeutics LLC, an Ohio corporation (“ Abeona OH ” and, together with Abeona and MacroChem, each individually, a “ Company ” and collectively, the “ Companies ”) entered into a Loan and Security Agreement (the “ Agreement ”)…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in